IL23R(Arg381Gln) functional polymorphism is associated with active pulmonary tuberculosis severity

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1188-1192

  Ben Selma, Walid ^a   Boukadida, Jalel ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMINE; INTERLEUKIN 23 RECEPTOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFECTION RISK; INTERLEUKIN 23 RECEPTOR GENE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MUTATOR GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; TUBERCULOSIS, PULMONARY; TUNISIA; YOUNG ADULT;

EID: 84864549414     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00135-12     Document Type: Article

References (47)

1. American Thoracic Society. 2000. Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 161:1376-1395.
2. Aujla SJ, Dubin PJ, Kolls JK. 2007. Th17 cells and mucosal host defense. Semin. Immunol. 19:377-382. (Pubitemid 351274047)
3. Barnes DS. 2000. Historical perspectives on the etiology of tuberculosis. Microbes Infect. 2:431-440.
4. Beck JS, Lowe JG, Grange JM. 1993. Corticosteroids as a risk factor for tuberculosis. Tuber. Lung Dis. 74:413-414.
5. Begum NA, et al. 2004. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect. Immun. 72:937-948. (Pubitemid 38166674)
6. Belladonna ML, et al. 2002. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168:5448-5454. (Pubitemid 34556122)
7. Ben-Selma W, Ben-Abderrahmen Y, Boukadida J, Harizi H. 2012. IL-10R1 S138G loss-of-function polymorphism is associated with extrapulmonary tuberculosis risk development in Tunisia. Mol. Biol. Rep. 39:51-56.
8. Brereton CF, et al. 2011. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J. Immunol. 186:5896-5906.
9. Carvalho A, et al. 2010. Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant. 45:1645-1652.
10. Casanova JL, Abel L. 2002. Genetic dissection of immunity to mycobacteria. The human model. Annu. Rev. Immunol. 20:581-620. (Pubitemid 34293435)
11. Chung DR, et al. 2003. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J. Immunol. 170:1958-1963. (Pubitemid 36197415)
12. Cooper AM, Khader SA. 2007. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 28:33-38. (Pubitemid 44960157)
13. Cooper AM, et al. 2002. Mice lacking bioactive IL-12 can generate protective, antigen specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 168:1322-1327. (Pubitemid 34094502)
14. Crofton J. 1990. Clinical features of tuberculosis, p. 395-421. In Seaton A, et al (ed), Crofton and Douglas's respiratory diseases. Blackwell Scientific, London, United Kingdom.
15. Cua DJ, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748. (Pubitemid 36227625)
16. de Paus RA, van de Wetering D, van Dissel JT, van de Vosse E. 2008. IL-23 and IL-12 responses in activated human T cells retrovirally transduced with IL-23 receptor variants. Mol. Immunol. 45:3889-3895.
17. Di Meglio P, et al. 2011. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 6:e17160. doi:10.1371/journal.pone.0017160.
18. Dubin PJ, Kolls JK. 2007. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L519-L528.
19. Flynn JL. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 84:93-101. (Pubitemid 38087953)
20. Gao L, Tao Y, Zhang L, Jin Q. 2010. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 14:15.
21. Happel KI, et al. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170:4432-4436. (Pubitemid 36519946)
22. Happel KI, et al. 2005. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun. 73:5782-5788. (Pubitemid 41193014)
23. Harrington LE, et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-1132. (Pubitemid 41541790)
24. Hölscher C, et al. 2001. A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. 167:6957-6966. (Pubitemid 33144190)
25. Hunter CA. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5:521-531. (Pubitemid 40961330)
26. Khader SA, et al. 2011. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J. Immunol. 187:5402-5427.
27. Khader SA, et al. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 175:788-795. (Pubitemid 41094960)
28. Kikly K, Liu L, Na S, Sedgwick JD. 2006. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18:670-675. (Pubitemid 44635178)
29. Kleinschek MA, et al. 2006. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J. Immunol. 176:1098-1106. (Pubitemid 43099711)
30. Langrish CL, et al. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202:96-105. (Pubitemid 39576907)
31. Lieberman LA, et al. 2004. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173:1887-1893. (Pubitemid 38971623)
32. Maher D, Chaulet P, Spinaci S, Harries A. 1997. Treatment of tuberculosis - guidelines for national programmes, p. 1-78. World Health Organization, Geneva, Switzerland.
33. Mangan PR, et al. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441:231-234.
34. Oppmann B, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725.
35. Park H, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-1141. (Pubitemid 41541791)
36. Pidasheva S, et al. 2011. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One 6:e25038. doi:10.1371/journal.pone.0025038.
37. Rodriguez S, Gaunt TR, Day IN. 2009. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169:505-514.
38. Sarin R, Wu X, Abraham C. 2011. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+and CD8+ human T-cell functional responses. Proc. Natl. Acad. Sci. U. S. A. 108:9560-9565.
39. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. 2007. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 178:4466-4472. (Pubitemid 46492398)
40. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146. (Pubitemid 37328691)
41. Van de Wetering D, de Paus RA, van Dissel JT, van de Vosse E. 2009. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int. Immunol. 21:145-153.
42. Venegas M, et al. 2008. IL-23R Arg381Gln polymorphism in Chilean patients with inflammatory bowel disease. Eur. Cytokine Netw. 19:190-195.
43. Verreck FA, et al. 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 101:4560-4565. (Pubitemid 38437450)
44. Wilson NJ, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8:950-957.
45. World Health Organization. 2011. Global tuberculosis control. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ global-report/en/.
46. World Health Organization. 2011. Tuberculosis. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/country/data/profiles/en/index.html.
47. Yu JJ, Ruddy MJ, Conti HR, Boonanantanasarn K, Gaffen SL. 2008. The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect. Immun. 76:4206-4213.